Rexahn Pharmaceuticals announced preliminary results for its drug candidate, Zoraxel from a Phase 2a study for the treatment of erectile dysfunction (ED). The double blind, randomized, placebo-controlled, dose ranging study found that male patients ages 18-65 treated with Zoraxel demonstrated improved erectile function as measured by changes over the International Index of Erectile Function (IIEF) baseline score within the 8-week treatment period.

Zoraxel is a centrally-acting, dual enhancer of brain neurotransmitters. Zoraxel is being developed as an oral tablet for on-demand use as a more effective ED treatment for patients who are responsive or unresponsive to PDE-5 inhibitors.

For more information call (240) 268-5300 or visit www.rexahn.com.